Boehringer Ingelheim

Feb 27, 2024

Survodutide Phase II trial Shows Groundbreaking Results in Liver Disease; GSK Announces Positive Headline Results from EAGLE-1 Phase III Trial; Dupixent sBLA Accepted for FDA Priority Review; Biogen’s QALSODY Received Positive Opinion from CHMP; FDA Granted Orphan Drug Designation to Immune-Onc’s IO-202; Artiva Biotherapeutics’s AlloNK® in Lupus Nephritis

Oct 10, 2023

Amgen to Acquire Horizon Therapeutics; Sanofi and Teva Announce Collaboration; Boehringer Obesity Drug Trial Update; FDA Places Partial Clinical Hold on IND for Lacutamab in CTCL/PTCL; Anaptys Announces Phase 3 Clinical Trial Results of Imsidolimab; Orphan Drug Designation to GC Biopharma’s GC1126A

Jun 27, 2023

FDA Approves Jardiance for Type 2 Diabetes; FDA Approves Pfizer’s LITFULO for Alopecia Areata; Sarepta Therapeutics’s ELEVIDYS Approval; Tonix Pharmaceuticals to Acquire Two Migraine Products from Upsher-Smith; FibroGen’s Phase 3 ZEPHYRUS-1 Study of Pamrevlumab; FDA Orphan Drug Designation to ERAS-801 for Malignant Glioma

Aug 10, 2020

Boehringer Ingelheim; Roche demonstrated new analyses of their drugs in patients with ILDs during the American Thoracic Society (ATS) Virtual conference

Mar 11, 2020

Ofev’s expanded use; Arkin Bio-Ventures II launch; USD 125 M for COVID-19 treatment

Jan 14, 2020

Eli Lilly to acquire Dermira, Boehringer buys Enleofen’s IL-11 platform, Biogen acquires Pfizer’s Alzheimer’s drug

Sep 23, 2019

Boehringer Ingelheim ties up with Inflammasome Therapeutics

Sep 09, 2019

FDA approves Ofev for interstitial lung disease

Nov 10, 2017

Business Cocktail

Feb 10, 2017

Chronic Kidney Disease: Complex Debilitating Condition

Newsletter/Whitepaper